US20200171282A1 - System and method for treatment of the claudification of the superficial femoral and proximal popliteal artery - Google Patents
System and method for treatment of the claudification of the superficial femoral and proximal popliteal artery Download PDFInfo
- Publication number
- US20200171282A1 US20200171282A1 US16/702,767 US201916702767A US2020171282A1 US 20200171282 A1 US20200171282 A1 US 20200171282A1 US 201916702767 A US201916702767 A US 201916702767A US 2020171282 A1 US2020171282 A1 US 2020171282A1
- Authority
- US
- United States
- Prior art keywords
- treating
- blockage
- femoral artery
- superior femoral
- sfa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 238000011282 treatment Methods 0.000 title claims description 23
- 210000003137 popliteal artery Anatomy 0.000 title abstract description 13
- 210000001105 femoral artery Anatomy 0.000 claims abstract description 54
- 238000002399 angioplasty Methods 0.000 claims description 42
- 210000003127 knee Anatomy 0.000 claims description 21
- 210000003414 extremity Anatomy 0.000 claims description 19
- 230000003902 lesion Effects 0.000 claims description 18
- 230000003073 embolic effect Effects 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 abstract description 2
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 description 23
- 238000013459 approach Methods 0.000 description 21
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000002224 dissection Methods 0.000 description 17
- 238000001356 surgical procedure Methods 0.000 description 17
- 206010022562 Intermittent claudication Diseases 0.000 description 16
- 206010034576 Peripheral ischaemia Diseases 0.000 description 16
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 15
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 15
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 15
- 230000000250 revascularization Effects 0.000 description 14
- 210000003141 lower extremity Anatomy 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 10
- 208000031481 Pathologic Constriction Diseases 0.000 description 9
- 210000003484 anatomy Anatomy 0.000 description 9
- 208000024980 claudication Diseases 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 238000012276 Endovascular treatment Methods 0.000 description 7
- 208000021156 intermittent vascular claudication Diseases 0.000 description 7
- 210000002414 leg Anatomy 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000013171 endarterectomy Methods 0.000 description 6
- 210000004013 groin Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 210000003041 ligament Anatomy 0.000 description 6
- 230000003143 atherosclerotic effect Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 208000037804 stenosis Diseases 0.000 description 5
- 210000004304 subcutaneous tissue Anatomy 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000002583 angiography Methods 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 238000002324 minimally invasive surgery Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000013439 planning Methods 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003099 femoral nerve Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 201000002818 limb ischemia Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 229920000260 silastic Polymers 0.000 description 3
- 206010062542 Arterial insufficiency Diseases 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000078511 Microtome Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010968 computed tomography angiography Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012282 endovascular technique Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000007892 surgical revascularization Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013151 thrombectomy Methods 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010068057 Dependent rubor Diseases 0.000 description 1
- 206010016451 Femoral nerve injury Diseases 0.000 description 1
- 206010056559 Graft infection Diseases 0.000 description 1
- 206010051269 Graft thrombosis Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 206010048625 Skin maceration Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047228 Venous injury Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009556 duplex ultrasonography Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003111 iliac vein Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000024977 response to activity Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000002465 tibial artery Anatomy 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320725—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with radially expandable cutting or abrading elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22001—Angioplasty, e.g. PCTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22051—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22051—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
- A61B2017/22061—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation for spreading elements apart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22081—Treatment of vulnerable plaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
Definitions
- the instant system relates generally to medical devices, including surgical and medical delivery systems, and more particularly to a method for the treatment of the claudification of the SFA and PPA.
- Peripheral arterial disease is a common manifestation of atherosclerosis affecting 5 million adults in the United States, with an age-adjusted prevalence of 4% to 15% and increasing up to 30% with age and the presence of cardiovascular risk factors.
- PAD Peripheral arterial disease
- SFPA superficial femoral and proximal popliteal artery
- Chronic lower extremity ischemia also classified as PAD, is a common condition managed by vascular specialists.
- the primary etiology is atherosclerosis.
- Atherosclerotic stenosis or occlusion of the peripheral arterial tree results in arterial insufficiency and end-organ (limb) ischemia.
- PAD is a major contributor to morbidity, reduced quality of life (QOL), and mortality in an increasing elderly demographic in the Western world.
- peripheral vascular disease As the population ages, it is anticipated that the prevalence of peripheral vascular disease will increase. Within the past decade there has been an unprecedented evolution of the endovascular technologies and vital improvements are expected in the next decade. Percutaneous procedures will continue to replace open surgery. The chief challenge in the management of peripheral arterial disease would be retooling of the health system to focus on identifying patients with PAD and taking the enormous opportunity and responsibility to refine and aggressively manage the atherosclerotic risk factors in these patients.
- the superficial femoral artery is a continuation of the common femoral artery at the point where the profunda femoris branches. It is the main artery of the lower limb and is, therefore, critical in the supply of oxygenated blood to the leg.
- Endovascular surgery is an innovative, less invasive procedure used to treat problems affecting the blood vessels, such as an aneurysm, which is a swelling or “ballooning” of the blood vessel.
- the surgery involves making a small incision near each hip to access the blood vessels.
- An endovascular graft which is a special fabric tube device framed with stainless steel self-expanding stents, is inserted through the arteries in a catheter, a long, narrow flexible tube, and positioned inside the aorta. Once in place, the graft expands and seals off the aneurysm, preventing blood from flowing into the aneurysm. The graft remains in the aorta permanently.
- intravascular translesional pressure gradients have been recommended to determine whether these lesions are hemodynamically significant and to predict patient improvement after revascularization.
- diagnostic translesional pressure gradient criteria the most widely accepted criteria utilize a mean gradient of 10 mmHg before or after vasodilators; or a mean gradient of 5 mmHg and peak systolic gradient of 10, 15 or 20 mmHg; or 15% peak systolic pressure gradient after administration of a vasodilator.
- the TASC II consensus emphasizes more anatomic criteria and recommends endovascular revascularization for type A lesions and surgery for type D lesions, whereas endovascular treatment is preferred for type B lesions and surgery for good-risk patients with type C lesions.
- Minimally invasive surgery is a surgery minimizing surgical incisions to reduce trauma to the body. This type of surgery is usually performed using thin-needles and an endoscope to visually guide the surgery.
- doctors use a variety of techniques to operate with less damage to the body than with open surgery. In general, minimally invasive surgery is associated with less pain, a shorter hospital stay and fewer complications.
- the type of revascularization should be elected based on different variables, such as location and severity of disease, anatomy, general medical condition, prior revascularization attempts and the desired outcome.
- inflow problems are corrected first, since improvement of the inflow may diminish the symptoms of claudication and reduce the likelihood of distal graft thrombosis from low flow.
- SFPA superficial femoral and proximal popliteal artery
- the superior rates of immediate and long-term patency rates favor autogenous vein grafts as opposed to prosthetic conduits for both above- or below-the-knee bypasses.
- the 5-year patency rates of femoropopliteal bypass grafts are reported as 80% for vein grafts, 75% for above-the-knee synthetic grafts and 65% for below-the-knee synthetic grafts.
- Patients undergoing surgical bypass for lower extremity ischemia should be entered into a clinical surveillance program that consists of interval history and vascular exam as well as measurement of resting and, if possible, post-exercise ABIs and duplex imaging of the entire length of the graft with measurements of peak systolic velocities and calculation of the velocity ratios across all lesions in the immediate postoperative period and at regular intervals (usually every 6 months) for at least 2 years.
- PTA percutaneous transluminal angioplasty
- balloon dilation stents
- endografts atherectomy
- laser cutting balloons
- drug-coated balloon angioplasty cryoplasty
- percutaneous thrombectomy percutaneous thrombectomy and brachytherapy
- the challenge for the vascular specialist is to determine whether the nature and severity of presenting symptoms correlate with the degree of chronic arterial insufficiency present or whether alternative etiologies, such as neuropathy, inflammation, infection, lymphatic or venous disease, and repetitive trauma, are more likely responsible. Definitive diagnosis is derived from detailed historic and physical examination findings correlated with appropriately directed noninvasive vascular laboratory and adjunctive imaging studies.
- CLI has been traditionally defined as (1) persistent, recurring ischemic rest pain requiring opiate analgesia for more than 2 weeks and (2) ankle systolic pressure less than 50 mmHg or toe systolic pressure less than 30 mmHg (or absent pedal pulse in patients with diabetes).
- Ischemic rest pain typically is nocturnal, worsens with elevation, and is relieved by dependency.
- Pedal pulses are absent; dependent rubor, elevation pallor, and calf muscle atrophy are frequent accompaniments.
- CLI also includes ischemic foot ulceration and gangrene in the setting of ankle systolic pressure less than 50 to 70 mmHg or toe systolic pressure less than 40 mmHg in patients without diabetes ( ⁇ 50 mmHg in diabetics).
- Revascularization is indicated in patients who remain symptomatic and significantly limited despite adequate risk factor modification, exercise, and medical management.
- the primary goal of intervention, in patients with lifestyle-limiting claudication, is to improve exercise tolerance and hence QOL.
- Patients with rest pain, tissue loss, and gangrene are at greater risk for limb loss and cardiovascular mortality (stroke, myocardial infarction) associated with systemic atherosclerosis than those who present with claudication alone.
- Revascularization in the critical limb ischemia (CLI) cohort is focused on wound healing and functional limb salvage as well as symptomatic relief and improvement in QOL.
- the vascular specialist must first determine, given the underlying disease burden, the severity of ischemic and infectious complications as well as the patient's comorbidities, functional status, and anticipated longevity. Once it is decided that revascularization will improve the patient's functional status and QOL, these same variables, in concert with anatomic assessment of the location, extent, and severity of occlusive arterial lesions will determine whether endovascular, open, or hybrid revascularization options are indicated.
- bypass is selected as the preferred revascularization option
- the goals of preoperative planning involve delineation of diseased arterial segment(s), identification of the most appropriate arterial inflow source, selection of the optimal bypass target for maximal outflow and target bed perfusion, and selection of the best available conduit. In practice, conduit availability is almost always a critical, rate-limiting factor because good quality, autogenous vein conduit is preferred in almost every circumstance.
- Adequate preoperative planning depends on a thorough history and detailed physical examination and thus the delineation of the relevant arterial anatomy on the index limb is facilitated by high quality, noninvasive vascular laboratory studies (ankle-brachial index and toe pressure measurements). These are supplemented by arterial color duplex ultrasound imaging. Arterial duplex is extremely accurate in the assessment of iliofemoral and femoropopliteal arterial occlusive disease but less so for intibiate (tibial-peroneal) lesions. Duplex enables differentiation of stenosis from occlusion and determination of lesion length and degree of calcification.
- CTA computed tomography angiography
- MRA magnetic resonance arteriography
- PAD is a coronary artery disease equivalent. Therefore, preoperative risk evaluation for overall cardiovascular-related mortality represents a component of preoperative planning. In most patients with stable or minimally symptomatic coronary disease, preoperative risk-reduction efforts are best focused on optimizing medical management. Frequently, this includes statin and antiplatelet therapy, ⁇ -blockade, and optimization of hypertension management.
- the surgical plan should be tailored to each patient's needs based on extent of disease, conduit availability, and realistic long-term functional potential. Infrainguinal bypass may originate from the common, superficial, or deep femoral artery or the popliteal artery with a bypass target of the popliteal, tibial, or pedal/plantar arteries. The positioning, choice of incisions, and surgical techniques are dictated by type of bypass procedure deemed most appropriate under the circumstance.
- the patient may be placed in a supine position and a Foley catheter is inserted. Arms may be tucked to facilitate intraoperative prebypass and completion angiography.
- the common femoral artery is located on a line between the pubic tubercle and anterior iliac spine, two fingerbreadths lateral to pubic tubercle. Palpation. of the inguinal ligament and femoral pulse or direct arterial visualization with duplex imaging can localize the CFA bifurcation and guide optimal incision placement. Even when pulseless due to excessive calcification or occlusive disease, the CFA may be localized by reliance on anatomic landmarks and direct palpation, recognized as a firm tubular structure positioned within the femoral sheath.
- the vertical groin incision is most commonly employed to provide optimal access to the entire length of the CFA. This should be created coaxially along the artery itself, continued from the inguinal ligament distally, and aimed at the medial aspect of the knee. The incision can be extended superiorly or inferiorly to increase arterial exposure as necessary to achieve optimal inflow.
- a curvilinear incision can be placed 1 cm below and parallel to the inguinal ligament to avoid potential skin maceration and wound complications that may accompany vertical incisions in this situation.
- the proximal superficial femoral and deep femoral arteries can be exposed via this incision, such a curvilinear or oblique incision limits further distal arterial exposure. It therefore would not be selected if an extensive common and deep femoral artery endarterectomy is anticipated as potentially necessary to optimize inflow.
- the incision is carried sharply through the subcutaneous tissue and superficial fascia.
- the dissection is extended longitudinally, even when using an oblique incision, to optimize the length of femoral exposure.
- self-retaining Weitlaner or cerebellar retractors are carefully placed to optimize exposure while avoiding traction injury to femoral nerve branches or the common femoral vein. Further dissection through the femoral sheath exposes the anterior surface of the femoral artery.
- the dissection plane should remain centered directly over the femoral artery. Encountering venous structures indicates medial deviation from the optimal plane; exposure of the iliopsoas muscle, femoral nerve fibers, or lymphatic vessels is an indication of lateral deviation. An increasing incidence of femoral incisional complications, including wound edge necrosis and separation, lymphatic leaks, femoral neuropraxia, and venous injuries are associated with incorrectly placed inguinal incisions for femoral exposure.
- the inguinal ligament may be divided to aid in exposure or to enable extended endarterectomy. Caution is necessary in this area, as a prominent femoral vein tributary crosses anteriorly over the CFA in this area and is prone to injury if not identified, ligated, and divided early in the dissection. Inadvertent injury to this “vein of pain” produces retraction and troublesome bleeding.
- the medial and lateral femoral circumflex arteries are identified at level of the inguinal ligament and individually controlled with removable clips or silastic vessel loops. Use of the former reduces clutter in the wound during endarterectomy or creation of the proximal anastomosis.
- an abrupt change in caliber marks the femoral bifurcation and the origins of the deep (also known as “ profunda femoris ” in Latin) and superficial femoral arteries (SFA).
- the latter continues distally in the same plane; the former usually courses posteriorly and laterally away from the femoral bifurcation.
- silastic loops are placed on each vessel, gentle upward traction on the CFA or SFA may help bring the deep femoral artery into view.
- the lateral circumflex iliac vein may course anteriorly over the origin of the deep femoral artery and should be ligated and divided to optimize exposure and control of the first segment of this vessel.
- Medial and distal dissection provides extended exposure of the proximal SFA.
- This vessel only occasionally has small branches in its proximal segment.
- a sensory branch of the femoral nerve may be present crossing the SFA from lateral to medial. Transection may result in medial thigh discomfort.
- Even extended femoral bifurcation dissections rarely require division of femoral nerve branches, which should be avoided to minimize postoperative paresthesias and dysesthesias.
- Exposure of the distal portions of the deep femoral artery often enables use of shorter vein conduit in distal leg bypass or may improve outflow from proximal revascularization procedures (iliac angioplasty and stenting or aortofemoral bypass). These segments are easily exposed from either posteromedial or anteromedial approaches. The approach should be dictated by the indication (inflow sources or outflow target); an additional consideration is the necessity to obtain exposure in a native field, either in the setting of prior dissection or femoral graft infection.
- Incisions are placed along either the medial (anteromedial approach; or lateral borders (posterolateral approach) of the sartorius muscle
- the dissection plane is developed through the subcutaneous tissue and fascia, passing lateral or medial to the sartorius, respectively. Mobilize and retract sartorius muscle laterally or medially, depending on approach.
- an operation can be used to remove the plaque from the artery in order to improve flow and circulation.
- the artery is close to the surface here under the skin, and therefore the surgical procedure is not too invasive.
- An alternative treatment would be angioplasty with a stent if required. This can be done with access to the arterial system from the opposite groin or arm to perform this procedure.
- the surgical procedure can be performed under general or local anaesthetic.
- the plaque is removed from the artery.
- a patch is often used to repair the artery and avoid narrowing.
- the patient will normally stay in hospital 1 or 2 nights following this procedure.
- the endarterectomy operation (removal of material on the inside of the artery) can be combined with angioplasty and stenting to treat these other areas at the same time. This combined or “hybrid” procedure is more common now and it achieves a better restoration of the circulation than the endarterectomy procedure alone.
- PAD of the SFA is the most common cause of intermittent claudication.
- Atherosclerotic disease of the SFA is localized to the region of Hunter's canal.
- An isolated occlusion or stenosis of the SFA often results in decreased perfusion of the leg, resulting in demand related, reversible, ischemic pain localized to the calf.
- Ischemic rest pain and tissue loss also known as CLI, are uncommon manifestations of isolated SFA disease. CLI is more commonly observed when occlusive disease of the SFA is combined with occlusive disease involving the below knee popliteal artery or tibial arteries.
- percutaneous transluminal angioplasty is a minimally invasive technique for treatment of superficial femoropopliteal artery (SFPLA) obstructions or occlusions in patients with intermittent claudication as well as critical limb ischemia.
- SFPLA superficial femoropopliteal artery
- endovascular stents With the introduction of endovascular stents, the problems of elastic recoil and residual stenoses due to arterial dissection could be resolved and initial reports of stenting for the treatment of occlusive atherosclerotic disease of the SFPLA have exhibit positive results.
- cutting balloons may be suited for as the balloon-mounted microtomes guarantee smooth lumen gain within the stent, without the risk of vessel wall perforation.
- Initial reports of the use of the cutting balloon for the treatment of occlusive atherosclerotic disease of the SFPLA show promising results, indicating that the problems of elastic recoil and residual stenoses due to arterial dissection might be resolved.
- the cutting balloon has four tiny microtomes ( ⁇ 0.1 mm height) on the outside, which cut the fibrous plaque during expansion of the balloon. Consequently the problem of elastic recoil is ideally addressed, additionally less trauma is exercised on the vessel wall during dilatation of the balloon.
- PTA has the advantage of being inexpensive and technically simpler than primary stenting, and is especially well looked upon as only PTA alone avoids utilization of foreign bodies that may be a potential stimulus for intimal hyperplasia. Another benefit of using PTA alone includes avoiding material fatigue and fractures associated with stenting wherein fatigue and fracture may result from the torque and deformation of the femoropopliteal arteries that occurs during flexion of the knee joint.
- angioplasty balloons allow PTA of the SFA through vascular sheaths as small as 4 French. Smaller sheath diameters result in fewer complications, and therefore, are considered safer.
- ease of re-intervention or bypass of an angioplastied arterial segment following PTA may be advantageous.
- the presence of a stent may impede endovascular re-intervention if a re-stenosis results in occlusion of the stented arterial segment.
- angioplasty preserves collateral vessels that may be compromised by stent placement.
- RSFAE Remote superficial femoral artery endarterectomy
- the femoral artery is the main blood vessel in your thigh that carries blood and oxygen to the legs. Plaques are fat, cholesterol, or tissues that are clogged in the inner wall of the artery. When plaques build up inside the superficial femoral artery, blood flow to the legs may be decreased. RSFAE may be done to relieve problems caused by a narrowed or blocked artery. Problems that may happen include severe pain in the hip, thigh, calf, or foot, and trouble when walking. Having these problems may decrease a person's ability to do his daily activities and affect his quality of life.
- RSFAE the plaque that blocks the artery is removed through a small incision (cut) in the groin.
- the groin is the area where your abdomen (stomach) meets your upper leg.
- Caregivers strip, cut, and remove the plaque by using different tools inserted through the SFA. This is done using a special type of x-ray as a guide.
- RSFAE may be followed by other procedures, such as angioplasty and stenting to open the artery using a small, high pressure balloon and implant a metal or plastic stent, in the area where the blockage was removed, to keep the artery open.
- a guide catheter can be advanced in stages with a balloon or a guidewire can be advanced independently to access the most proximal location in the vessel prior to introduction of the balloon catheter and paving can advance proximal to distal.
- the instant system, method and set of accompanying apparatuses allow for retrograde access to the superficial femoral artery for treatment of blockages and restoration of proper blood flow to vital pathways.
- an objective of the instant system to introduce a method wherein a vessel more superficial compared to femoral is utilized for access and thus requiring a smaller puncture which is particularly advantageous in the more obese patients.
- An object of the instant system to introduce a series of devices and a method for endovascular treatment of SFPA disease is indicated for individuals with significant disability due to intermittent claudication or critical limb ischemia.
- the column strength of guide catheter can break through heavily calcified lesion and operate in combination with low profile balloon catheter can pave way proximal through the SFA.
- PTA percutaneous transluminal angioplasty
- the guide catheter can be advanced in stages with the balloon or the guidewire can be advanced independently to access the most proximal location in the vessel prior to introduction of the balloon catheter and paving can advance proximal to distal (i.e in the direction of the puncture site).
- FIG. 1 illustrates cross sectional view of a human limb further illustrating the anatomy of the limb with the arteries highlighted and further illustrating an access point for a retrograde approach to treating blockages of the lower portion of the superficial femoral artery or lower SFA.
- FIG. 2 illustrates a cross sectional view of the procedural tract illustrating the access point for retrograde approach to treating blockages of the lower SFA. Further illustrated is the puncture site for sheath access through Popliteal behind the knee.
- the system being utilized introduces a 3F introducer sheath, a guide catheter for advancing toward an area of dense plaque within the lower SFA and a balloon in a deflated orientation. The blood flow direction is illustrated and thus retrograde access is being performed herein.
- FIG. 3 illustrates cross sectional view of the access point for retrograde approach to treating blockages of the lower SFA. Further illustrated is the puncture site for sheath access through Popliteal behind the knee.
- the system being utilized introduces a 3F introducer sheath, a guide catheter for advancing toward an area of dense plaque within the lower SFA and a balloon in an inflated orientation in order to free up the blockage in a retrograde paving technique which opens up the calcified lesion.
- FIG. 4 illustrates a right side view, detailed cutaway of the anatomy of limb showing access point for retrograde approach to treating lower SFA, illustrating the full path for entry and delivery from the popliteal entry to superficial femoral artery.
- FIG. 5 illustrates a left side view, detailed cutaway of the anatomy of the limb showing access point for retrograde approach to treating lower SFA, illustrating the entirety of the entry and delivery path from the popliteal entry to superficial femoral artery in the color green.
- the pathway is illuminated from the puncture site through popliteal behind the knee to the blockage are in the lower SFA.
- FIG. 1 illustrates a cross sectional view of a human limb further illustrating the anatomy of the limb with the arteries highlighted and further illustrating an access point 10 for a retrograde approach to treating blockages of the lower superficial femoral artery (SFA).
- SFA lower superficial femoral artery
- FIG. 2 illustrates a cross sectional view of the procedural tract 5 illustrating the access point 10 for retrograde approach to treating blockages of the lower SFA, further illustrating the instrumentation utilized at the access point 10 or the puncture site and for sheath access through the Popliteal and popliteal artery 15 behind the knee.
- the system being utilized introduces an introducer sheath 20 , a guide catheter 30 for advancing toward an area of dense plaque 40 within the lower SFA 50 and a balloon 60 in a deflated orientation.
- the introducer sheath 20 utilized may be a three French or 3F introducer sheath 20 .
- the blood flow direction indicator 70 is illustrated, thus denoting that retrograde access is being performed herein.
- a guide wire 80 may also be utilized in conjunction with the currently described system.
- FIG. 3 illustrates a further cross-sectional view of the procedural tract 5 illustrating the access point 10 and the system deployed further illustrating the access point 10 through the Popliteal and popliteal artery 15 behind the knee for retrograde approach to treating blockages of the lower SFA 50 . Further illustrated is the puncture site for sheath access through Popliteal behind the knee.
- the system being utilized introduces a 3F introducer sheath 20 , a guide catheter 30 for advancing toward an area of dense plaque 40 within the lower SFA 50 and the balloon 60 , now in the inflated orientation in order to free up the blockage in a retrograde paving technique which opens up the calcified lesion.
- the blood flow direction indicator 70 is illustrated, thus denoting that retrograde access is being performed herein. Additionally illustrated herein is a guidewire 80 , which may also be utilized.
- the guide catheter may be advanced in stages with the balloon.
- the guidewire may be advanced independently to access the most proximal location in the vessel prior to introduction of the balloon catheter and paving can advance proximal to distal (i.e in the direction of the puncture site).
- FIG. 4 illustrates a right-side view of a more detailed cutaway of the anatomy of the limb 100 illustrating the entirety of the entry and delivery tract 5 from the popliteal artery 15 entry to superficial femoral artery in the color green.
- the pathway is illuminated from the puncture site through popliteal behind the knee to the blockage are in the lower SFA.
- FIG. 5 illustrates a left side view, detailed cutaway of the anatomy of the limb 105 showing access point for retrograde approach to treating lower SFA, illustrating the entirety of the entry and delivery path 5 from the popliteal artery 15 entry to superficial femoral artery in the color green.
- the pathway is illuminated from the puncture site through popliteal behind the knee to the blockage are in the lower SFA.
- a method of treating a blockage of the superior femoral artery involves the steps of:
- an introducer sheath having a proximal end, a distal end, an opening at the distal end, and a passage in communication with the opening at the distal end, the one or more prostheses being movably disposed in the passage;
- the method includes the use of a guide wire and where it is advanced in stages.
- the introducer sheath comprises a three (3) French introducer sheath.
- the method includes additional steps of advancing the guidewire independently to access the most proximal location in a vessel and introducing a balloon.
- the method involves the steps of advancing the guide catheter and paving proximal to distal in the direction of the puncture site and advancing distal to proximal in order to reduce a shower of emboli below the knee into the territory of the foot.
- the method of treating a blockage of the superior femoral artery comprises the step of positioning an embolic protection device in the region proximal to the puncture site to permit safe removal of dislodged plaque or emboli generated during the access and angioplasty procedure and comprises the step of removing dislodged plaque or emboli generated during the access and angioplasty procedure.
- Another aspect of the method of treating a blockage of the superior femoral artery of claim 1 includes the step of advancing directly from the popliteal to the SFA and access not dealing with branch vessels allowing for navigation without wire and optionally utilizing a system which does not include the guide wire for navigation of the popliteal and SFA.
- the method of treating a blockage of the superior femoral artery of further comprises the step of selecting or calibrating a measure of column strength of the guide catheter can break through heavily calcified lesion and the step of operating in combination with a low-profile balloon catheter to advance proximally through the SFA.
- the method of treating a blockage of the superior femoral artery of further comprises the step of advancing the guide catheter in a method selected from the group consisting of in stages with a balloon and independently, and may also include the steps of:
- the method of treating a blockage of the superior femoral artery comprises the step of positioning an embolic protection device at or near the puncture site will permit safe removal of dislodged plaque or emboli generated during an access and angioplasty procedure and the step of utilizing a retrograde paving technique to open the calcified lesion.
- a system for treating a blockage of the superior femoral artery which includes:
- the system for treating a blockage of the superior femoral artery may utilize a low profile balloon catheter to pave proximal through the SFA, while maximizing the column strength of the guide catheter to break through heavily calcified lesion.
- a method of delivering one or more prostheses to a treatment site involves the steps of providing a catheter, and using a sheath having a proximal end, a distal end, an opening at the distal end, and a passage in communication with the opening, the one or more prostheses being movably disposed in the passage with an expandable member near the distal end of the sheath, the one or more prostheses being positionable over the expandable member, and a valve member near the distal end of the sheath adapted for selectively retaining a first set of prostheses within the passage and to engage the one or more prostheses whereby the one or more prostheses may be moved relative to the expandable member by moving the sheath; positioning the distal end of the sheath and the expandable member at the treatment site; and proximally retracting the sheath relative to the expandable member to move the valve member and thereby cause a first set of prostheses to pass through the opening of the sheath
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgical Instruments (AREA)
Abstract
A system and accompanying methods for treating a blockage of the superior femoral artery including utilization of a puncture insertion mechanism, an introducer sheath, a guide catheter and an expandable device. Entry into the body is established through the popliteal and advancing retrograde through the popliteal artery toward the lower superior femoral artery region and in some embodiments utilizing an introducer sheath, a guide catheter and a balloon are featured.
Description
- This application takes the benefit of and claims priority to U.S. Provisional Patent Application Ser. No. 62/775,055 filed on Dec. 4, 2018, the contents of which are herein incorporated by reference.
- The instant system relates generally to medical devices, including surgical and medical delivery systems, and more particularly to a method for the treatment of the claudification of the SFA and PPA.
- Peripheral arterial disease (PAD) is a common manifestation of atherosclerosis affecting 5 million adults in the United States, with an age-adjusted prevalence of 4% to 15% and increasing up to 30% with age and the presence of cardiovascular risk factors. In this article we focus on lower extremity PAD and specifically on the superficial femoral and proximal popliteal artery (SFPA), which are the most common anatomic locations of lower extremity atherosclerosis.
- Chronic lower extremity ischemia, also classified as PAD, is a common condition managed by vascular specialists. The primary etiology is atherosclerosis. Atherosclerotic stenosis or occlusion of the peripheral arterial tree results in arterial insufficiency and end-organ (limb) ischemia. PAD is a major contributor to morbidity, reduced quality of life (QOL), and mortality in an increasing elderly demographic in the Western world.
- As the population ages, it is anticipated that the prevalence of peripheral vascular disease will increase. Within the past decade there has been an unprecedented evolution of the endovascular technologies and vital improvements are expected in the next decade. Percutaneous procedures will continue to replace open surgery. The chief challenge in the management of peripheral arterial disease would be retooling of the health system to focus on identifying patients with PAD and taking the enormous opportunity and responsibility to refine and aggressively manage the atherosclerotic risk factors in these patients.
- The superficial femoral artery is a continuation of the common femoral artery at the point where the profunda femoris branches. It is the main artery of the lower limb and is, therefore, critical in the supply of oxygenated blood to the leg. Over the past decade there has been a remarkable advancement in the endovascular treatment of lower extremity PAD with the introduction of new interventional techniques and devices, and specifically on the SFPA, which are the most common anatomic locations of lower extremity atherosclerosis.
- Currently, endovascular treatment of SFPA disease is indicated for individuals with significant disability due to intermittent claudication or critical limb ischemia when clinical features suggest a reasonable likelihood of symptomatic improvement with endovascular intervention, there has been an inadequate response to exercise or pharmacological therapy and when there is a favorable risk-benefit ratio. Claudication is defined as muscular pain, cramping, aching, or discomfort in the lower limb, reproducibly elicited by exercise and relieved within 10 minutes of cessation.
- Endovascular surgery is an innovative, less invasive procedure used to treat problems affecting the blood vessels, such as an aneurysm, which is a swelling or “ballooning” of the blood vessel. The surgery involves making a small incision near each hip to access the blood vessels. An endovascular graft, which is a special fabric tube device framed with stainless steel self-expanding stents, is inserted through the arteries in a catheter, a long, narrow flexible tube, and positioned inside the aorta. Once in place, the graft expands and seals off the aneurysm, preventing blood from flowing into the aneurysm. The graft remains in the aorta permanently.
- Apart from the clinical and angiographic criteria for selection of patients for endovascular treatment, for stenoses of 50-75% diameter by angiography, intravascular translesional pressure gradients have been recommended to determine whether these lesions are hemodynamically significant and to predict patient improvement after revascularization. Although there is no consensus on the diagnostic translesional pressure gradient criteria, the most widely accepted criteria utilize a mean gradient of 10 mmHg before or after vasodilators; or a mean gradient of 5 mmHg and peak systolic gradient of 10, 15 or 20 mmHg; or 15% peak systolic pressure gradient after administration of a vasodilator. The TASC II consensus emphasizes more anatomic criteria and recommends endovascular revascularization for type A lesions and surgery for type D lesions, whereas endovascular treatment is preferred for type B lesions and surgery for good-risk patients with type C lesions.
- For some time, surgical revascularization has been the main form of treatment. Surgical treatment of lower extremity ischemia is indicated for patients with claudication and significant functional disability or critical limb ischemia, after failure of conservative or endovascular therapy, who have a reasonable likelihood of symptomatic improvement, favorable limb arterial anatomy and low cardiovascular risk for surgical revascularization. With the evolution of endovascular technology and interventional techniques, as well as their equivalent efficacy, lower cost and lower peri-procedural risk, surgery has become a second-line revascularization option and is currently recommended only for TASC D lesions.
- Furthermore, as surgery should be avoided in patients younger than 50 years old, since they have a more virulent form of atherosclerosis and subsequently a higher frequency of graft failure requiring revisions and replacement, minimally invasive surgery is plainly the better choice. Minimally invasive surgery is a surgery minimizing surgical incisions to reduce trauma to the body. This type of surgery is usually performed using thin-needles and an endoscope to visually guide the surgery. During minimally invasive surgery, doctors use a variety of techniques to operate with less damage to the body than with open surgery. In general, minimally invasive surgery is associated with less pain, a shorter hospital stay and fewer complications.
- Normally, once the decision to proceed with surgical intervention is undertaken, the type of revascularization should be elected based on different variables, such as location and severity of disease, anatomy, general medical condition, prior revascularization attempts and the desired outcome. As a general rule, in patients with combined inflow and outflow disease, inflow problems are corrected first, since improvement of the inflow may diminish the symptoms of claudication and reduce the likelihood of distal graft thrombosis from low flow. In the case of superficial femoral and proximal popliteal artery (SFPA) disease, two major factors that can modify the result of the procedure are the type of the conduit and the site of the distal anastomosis.
- The superior rates of immediate and long-term patency rates favor autogenous vein grafts as opposed to prosthetic conduits for both above- or below-the-knee bypasses. In some studies, the 5-year patency rates of femoropopliteal bypass grafts are reported as 80% for vein grafts, 75% for above-the-knee synthetic grafts and 65% for below-the-knee synthetic grafts. Patients undergoing surgical bypass for lower extremity ischemia should be entered into a clinical surveillance program that consists of interval history and vascular exam as well as measurement of resting and, if possible, post-exercise ABIs and duplex imaging of the entire length of the graft with measurements of peak systolic velocities and calculation of the velocity ratios across all lesions in the immediate postoperative period and at regular intervals (usually every 6 months) for at least 2 years.
- Major amputation in patients with critical or acute limb ischemia should be reserved only when the limb is unsalvageable, i.e., when there is overwhelming infection that threatens the patient's life, extensive necrosis or refractory ischemic rest pain.
- Currently, a wide variety of established and evolving endovascular techniques to treat PAD including percutaneous transluminal angioplasty (PTA) with balloon dilation, stents, endografts, atherectomy, laser, cutting balloons, drug-coated balloon angioplasty, cryoplasty, percutaneous thrombectomy and brachytherapy exist.
- The challenge for the vascular specialist is to determine whether the nature and severity of presenting symptoms correlate with the degree of chronic arterial insufficiency present or whether alternative etiologies, such as neuropathy, inflammation, infection, lymphatic or venous disease, and repetitive trauma, are more likely responsible. Definitive diagnosis is derived from detailed historic and physical examination findings correlated with appropriately directed noninvasive vascular laboratory and adjunctive imaging studies.
- Patients with PAD may present with a spectrum of symptoms ranging in severity from none to varying degrees of claudication to severe or “critical” limb ischemia. CLI has been traditionally defined as (1) persistent, recurring ischemic rest pain requiring opiate analgesia for more than 2 weeks and (2) ankle systolic pressure less than 50 mmHg or toe systolic pressure less than 30 mmHg (or absent pedal pulse in patients with diabetes). Ischemic rest pain typically is nocturnal, worsens with elevation, and is relieved by dependency. Pedal pulses are absent; dependent rubor, elevation pallor, and calf muscle atrophy are frequent accompaniments. CLI also includes ischemic foot ulceration and gangrene in the setting of ankle systolic pressure less than 50 to 70 mmHg or toe systolic pressure less than 40 mmHg in patients without diabetes (<50 mmHg in diabetics).
- All patients with PAD require comprehensive medical management and risk factor modification. Revascularization (either open bypass or endovascular intervention) is indicated in patients who remain symptomatic and significantly limited despite adequate risk factor modification, exercise, and medical management. The primary goal of intervention, in patients with lifestyle-limiting claudication, is to improve exercise tolerance and hence QOL. Patients with rest pain, tissue loss, and gangrene are at greater risk for limb loss and cardiovascular mortality (stroke, myocardial infarction) associated with systemic atherosclerosis than those who present with claudication alone. Revascularization in the critical limb ischemia (CLI) cohort is focused on wound healing and functional limb salvage as well as symptomatic relief and improvement in QOL.
- The vascular specialist must first determine, given the underlying disease burden, the severity of ischemic and infectious complications as well as the patient's comorbidities, functional status, and anticipated longevity. Once it is decided that revascularization will improve the patient's functional status and QOL, these same variables, in concert with anatomic assessment of the location, extent, and severity of occlusive arterial lesions will determine whether endovascular, open, or hybrid revascularization options are indicated. When bypass is selected as the preferred revascularization option, the goals of preoperative planning involve delineation of diseased arterial segment(s), identification of the most appropriate arterial inflow source, selection of the optimal bypass target for maximal outflow and target bed perfusion, and selection of the best available conduit. In practice, conduit availability is almost always a critical, rate-limiting factor because good quality, autogenous vein conduit is preferred in almost every circumstance.
- Adequate preoperative planning depends on a thorough history and detailed physical examination and thus the delineation of the relevant arterial anatomy on the index limb is facilitated by high quality, noninvasive vascular laboratory studies (ankle-brachial index and toe pressure measurements). These are supplemented by arterial color duplex ultrasound imaging. Arterial duplex is extremely accurate in the assessment of iliofemoral and femoropopliteal arterial occlusive disease but less so for infrageniculate (tibial-peroneal) lesions. Duplex enables differentiation of stenosis from occlusion and determination of lesion length and degree of calcification. Cross-sectional imaging studies such as computed tomography angiography (CTA) or magnetic resonance arteriography (MRA) may add complementary information, but most experienced operators prefer the precision and resolution inherent in catheter-based, intraarterial contrast arteriography for definitive preoperative planning, especially when bypass will be required to distal calf or pedal targets.
- PAD is a coronary artery disease equivalent. Therefore, preoperative risk evaluation for overall cardiovascular-related mortality represents a component of preoperative planning. In most patients with stable or minimally symptomatic coronary disease, preoperative risk-reduction efforts are best focused on optimizing medical management. Frequently, this includes statin and antiplatelet therapy, β-blockade, and optimization of hypertension management. The surgical plan should be tailored to each patient's needs based on extent of disease, conduit availability, and realistic long-term functional potential. Infrainguinal bypass may originate from the common, superficial, or deep femoral artery or the popliteal artery with a bypass target of the popliteal, tibial, or pedal/plantar arteries. The positioning, choice of incisions, and surgical techniques are dictated by type of bypass procedure deemed most appropriate under the circumstance.
- Discussing some state of the art techniques, including techniques utilizing vessel exposure, the patient may be placed in a supine position and a Foley catheter is inserted. Arms may be tucked to facilitate intraoperative prebypass and completion angiography.
- Regarding placement of an incision, the common femoral artery (CFA) is located on a line between the pubic tubercle and anterior iliac spine, two fingerbreadths lateral to pubic tubercle. Palpation. of the inguinal ligament and femoral pulse or direct arterial visualization with duplex imaging can localize the CFA bifurcation and guide optimal incision placement. Even when pulseless due to excessive calcification or occlusive disease, the CFA may be localized by reliance on anatomic landmarks and direct palpation, recognized as a firm tubular structure positioned within the femoral sheath.
- The vertical groin incision is most commonly employed to provide optimal access to the entire length of the CFA. This should be created coaxially along the artery itself, continued from the inguinal ligament distally, and aimed at the medial aspect of the knee. The incision can be extended superiorly or inferiorly to increase arterial exposure as necessary to achieve optimal inflow.
- Alternatively, especially in obese patients with substantial abdominal pannus, a curvilinear incision can be placed 1 cm below and parallel to the inguinal ligament to avoid potential skin maceration and wound complications that may accompany vertical incisions in this situation. Although the proximal superficial femoral and deep femoral arteries can be exposed via this incision, such a curvilinear or oblique incision limits further distal arterial exposure. It therefore would not be selected if an extensive common and deep femoral artery endarterectomy is anticipated as potentially necessary to optimize inflow. The incision is carried sharply through the subcutaneous tissue and superficial fascia.
- Investigating the state of the art for dissection and control of the common, superficial, and proximal deep femoral arteries, deep to the subcutaneous tissue and superficial fascia, the dissection is extended longitudinally, even when using an oblique incision, to optimize the length of femoral exposure. Depending on the depth of dissection and subcutaneous adiposity, self-retaining Weitlaner or cerebellar retractors are carefully placed to optimize exposure while avoiding traction injury to femoral nerve branches or the common femoral vein. Further dissection through the femoral sheath exposes the anterior surface of the femoral artery.
- The dissection plane should remain centered directly over the femoral artery. Encountering venous structures indicates medial deviation from the optimal plane; exposure of the iliopsoas muscle, femoral nerve fibers, or lymphatic vessels is an indication of lateral deviation. An increasing incidence of femoral incisional complications, including wound edge necrosis and separation, lymphatic leaks, femoral neuropraxia, and venous injuries are associated with incorrectly placed inguinal incisions for femoral exposure.
- Dissect directly along the CFA both proximally and distally. Placement of silastic vessel loops around the femoral artery and its larger branches aids in retraction, dissection, and mobilization. Proximal dissection is continued along the CFA to the inguinal ligament. The inguinal ligament may be divided to aid in exposure or to enable extended endarterectomy. Caution is necessary in this area, as a prominent femoral vein tributary crosses anteriorly over the CFA in this area and is prone to injury if not identified, ligated, and divided early in the dissection. Inadvertent injury to this “vein of pain” produces retraction and troublesome bleeding.
- The medial and lateral femoral circumflex arteries, important collaterals in iliofemoral arterial occlusive disease, are identified at level of the inguinal ligament and individually controlled with removable clips or silastic vessel loops. Use of the former reduces clutter in the wound during endarterectomy or creation of the proximal anastomosis.
- As the dissection proceeds distally, an abrupt change in caliber marks the femoral bifurcation and the origins of the deep (also known as “profunda femoris” in Latin) and superficial femoral arteries (SFA). The latter continues distally in the same plane; the former usually courses posteriorly and laterally away from the femoral bifurcation. After silastic loops are placed on each vessel, gentle upward traction on the CFA or SFA may help bring the deep femoral artery into view. The lateral circumflex iliac vein may course anteriorly over the origin of the deep femoral artery and should be ligated and divided to optimize exposure and control of the first segment of this vessel.
- Medial and distal dissection provides extended exposure of the proximal SFA. This vessel only occasionally has small branches in its proximal segment. A sensory branch of the femoral nerve may be present crossing the SFA from lateral to medial. Transection may result in medial thigh discomfort. Even extended femoral bifurcation dissections rarely require division of femoral nerve branches, which should be avoided to minimize postoperative paresthesias and dysesthesias.
- Exposure of the distal portions of the deep femoral artery often enables use of shorter vein conduit in distal leg bypass or may improve outflow from proximal revascularization procedures (iliac angioplasty and stenting or aortofemoral bypass). These segments are easily exposed from either posteromedial or anteromedial approaches. The approach should be dictated by the indication (inflow sources or outflow target); an additional consideration is the necessity to obtain exposure in a native field, either in the setting of prior dissection or femoral graft infection.
- Incisions are placed along either the medial (anteromedial approach; or lateral borders (posterolateral approach) of the sartorius muscle The dissection plane is developed through the subcutaneous tissue and fascia, passing lateral or medial to the sartorius, respectively. Mobilize and retract sartorius muscle laterally or medially, depending on approach.
- When the artery in the groin, the femoral artery, is stenosed or blocked, an operation can be used to remove the plaque from the artery in order to improve flow and circulation. The artery is close to the surface here under the skin, and therefore the surgical procedure is not too invasive. An alternative treatment would be angioplasty with a stent if required. This can be done with access to the arterial system from the opposite groin or arm to perform this procedure.
- Traditionally the long term results of surgery to remove the plaque when it is localized to the femoral artery have been better than angioplasty. However in certain patient's not suitable for surgery, and with improving; technology, angioplasty is being used more frequently Both treatments can therefore be used, the vascular surgical team will decide which treatment is the better approach for the situation at hand.
- The surgical procedure can be performed under general or local anaesthetic. The plaque is removed from the artery. A patch is often used to repair the artery and avoid narrowing. The patient will normally stay in hospital 1 or 2 nights following this procedure. If there is also disease with narrowed or blocked arteries elsewhere above the groin or further down the leg, the endarterectomy operation (removal of material on the inside of the artery) can be combined with angioplasty and stenting to treat these other areas at the same time. This combined or “hybrid” procedure is more common now and it achieves a better restoration of the circulation than the endarterectomy procedure alone.
- Further investigating the current state of lower extremity revascularization for patients with claudication and critical limb ischemia. Regarding treatment of the SFA for claudicative diseases, currently revascularization through an endovascular approach has become the default method for therapy in most, if not all, vascular beds (intricate network of minute blood vessels that ramifies through the tissues of the body or of one of its parts). The treatment for peripheral arterial obstructive disease in the lower extremity is no exception.
- The quandary faced by the industry, and thus many of the questions asked revolve around whether or not to treat only when the claudication is at its worse or treat more aggressively and early, as this impacts potential heart-healthy lifestyles. Other key issues broach whether drug-delivery balloons and the current stent designs are not the correct systems for the SFA and whether changes to stent technologies—woven stents, alternatively designed stents or very conformable stents—define the future treatment directives.
- Thus, PAD of the SFA is the most common cause of intermittent claudication. Atherosclerotic disease of the SFA is localized to the region of Hunter's canal. An isolated occlusion or stenosis of the SFA often results in decreased perfusion of the leg, resulting in demand related, reversible, ischemic pain localized to the calf. Ischemic rest pain and tissue loss, also known as CLI, are uncommon manifestations of isolated SFA disease. CLI is more commonly observed when occlusive disease of the SFA is combined with occlusive disease involving the below knee popliteal artery or tibial arteries.
- As discussed above, percutaneous transluminal angioplasty (PTA) is a minimally invasive technique for treatment of superficial femoropopliteal artery (SFPLA) obstructions or occlusions in patients with intermittent claudication as well as critical limb ischemia. With the introduction of endovascular stents, the problems of elastic recoil and residual stenoses due to arterial dissection could be resolved and initial reports of stenting for the treatment of occlusive atherosclerotic disease of the SFPLA have exhibit positive results. However, subsequent studies demonstrated that exaggerated neo-intimal hyperplasia (proliferation and migration of vascular smooth muscle cells primarily in the tunica intima, resulting in the thickening of arterial walls and decreased arterial lumen space) in the stented segment frequently leads to instent restenosis.
- Also, cutting balloons may be suited for as the balloon-mounted microtomes guarantee smooth lumen gain within the stent, without the risk of vessel wall perforation. Initial reports of the use of the cutting balloon for the treatment of occlusive atherosclerotic disease of the SFPLA show promising results, indicating that the problems of elastic recoil and residual stenoses due to arterial dissection might be resolved. The cutting balloon has four tiny microtomes (<0.1 mm height) on the outside, which cut the fibrous plaque during expansion of the balloon. Consequently the problem of elastic recoil is ideally addressed, additionally less trauma is exercised on the vessel wall during dilatation of the balloon.
- This might be achieved by a reduction of vessel wall trauma, vessel wall inflammation and consequently reduced neointimal formation. Although the indications for cutting balloon angioplasty (CB-PTA) in the SFA includes significant residual stenosis or in-stent restenosis, there are currently no published randomized controlled trials (RCT) comparing PTA vs. CB-PTA for any specific condition. This lack of data led us to initiate a RCT comparing primary PTA vs. CB-PTA for treatment of in-stent restenoses in patients with intermittent claudication or critical limb ischemia with TASC category A-B in the femoropopliteal artery.
- Historically, endovascular treatment of the SFA was first described by Charles Dotter wherein he used Teflon coated dilators to sequentially angioplasty the SFA in an 82-year-old woman to treat critical limb ischemia that was considered non-operable. Subsequently, Gruntzig popularized the concept of catheter directed balloon angioplasty. Angioplasty disrupts the atherosclerotic plaque by displacing it radially and results in stretching of the adventitia thereby increasing the lumen diameter in the treated vessel. By definition, a dissection is created and if significant, can be flow limiting.
- Currently, the most commonly utilized endovascular revascularization options are percutaneous transluminal angioplasty (PTA) with provisional stenting or primary stenting. Provisional or selective stenting is indicated for the treatment of flow limiting dissections and/or persistent, hemodynamically significant stenoses or recoil after PTA. This approach is recommended by the Tran-Atlantic inter-Society Consensus document II (TASC II) when treating SFA disease. However, both PTA alone and primary stenting can successfully treat SFA disease. Therefore, the debate continues as to which endovascular treatment is superior.
- PTA has the advantage of being inexpensive and technically simpler than primary stenting, and is especially well looked upon as only PTA alone avoids utilization of foreign bodies that may be a potential stimulus for intimal hyperplasia. Another benefit of using PTA alone includes avoiding material fatigue and fractures associated with stenting wherein fatigue and fracture may result from the torque and deformation of the femoropopliteal arteries that occurs during flexion of the knee joint.
- Further, the advent of lower profile angioplasty balloons allows PTA of the SFA through vascular sheaths as small as 4 French. Smaller sheath diameters result in fewer complications, and therefore, are considered safer. In addition, the ease of re-intervention or bypass of an angioplastied arterial segment following PTA may be advantageous. The presence of a stent may impede endovascular re-intervention if a re-stenosis results in occlusion of the stented arterial segment. Moreover, angioplasty preserves collateral vessels that may be compromised by stent placement.
- The clear need for advancement is illustrated through the need to treat chronic limb ischemia arise when it results in the limb threatening conditions of rest pain and tissue loss and possible loss of limb illustrate the exigency. Debilitating symptoms of intermittent claudication, a condition in which cramping pain in the leg is induced by exercise, typically caused by obstruction of the arteries, may occur and intermittent claudication is the most common manifestation of isolated SFA arterial disease. Though SFA disease is often present in patients with CLI, it is frequently seen in conjunction with multi-level arterial occlusive disease.
- Remote superficial femoral artery endarterectomy (RSFAE) is a procedure to remove plaques inside the SFA. The femoral artery is the main blood vessel in your thigh that carries blood and oxygen to the legs. Plaques are fat, cholesterol, or tissues that are clogged in the inner wall of the artery. When plaques build up inside the superficial femoral artery, blood flow to the legs may be decreased. RSFAE may be done to relieve problems caused by a narrowed or blocked artery. Problems that may happen include severe pain in the hip, thigh, calf, or foot, and trouble when walking. Having these problems may decrease a person's ability to do his daily activities and affect his quality of life.
- With RSFAE, the plaque that blocks the artery is removed through a small incision (cut) in the groin. The groin is the area where your abdomen (stomach) meets your upper leg. Caregivers strip, cut, and remove the plaque by using different tools inserted through the SFA. This is done using a special type of x-ray as a guide. RSFAE may be followed by other procedures, such as angioplasty and stenting to open the artery using a small, high pressure balloon and implant a metal or plastic stent, in the area where the blockage was removed, to keep the artery open.
- In an advantageous manner, utilizing a retrograde approach to treat SFA with a PTA approach augments the overall capabilities. As an alternative, a guide catheter can be advanced in stages with a balloon or a guidewire can be advanced independently to access the most proximal location in the vessel prior to introduction of the balloon catheter and paving can advance proximal to distal.
- The instant system, method and set of accompanying apparatuses allow for retrograde access to the superficial femoral artery for treatment of blockages and restoration of proper blood flow to vital pathways.
- In one embodiment, it is an object of the instant system to introduce a retrograde stepwise paving approach to treat the SFA and particularly the lower SFA.
- It is an additional object of the instant system to introduce a method wherein a vessel more superficial compared to femoral is utilized for access and thus requiring a smaller puncture. In one embodiment, an objective of the instant system to introduce a method wherein a vessel more superficial compared to femoral is utilized for access and thus requiring a smaller puncture which is particularly advantageous in the more obese patients.
- An object of the instant system to introduce a series of devices and a method for endovascular treatment of SFPA disease is indicated for individuals with significant disability due to intermittent claudication or critical limb ischemia.
- In one embodiment, it is an object of the instant system to introduce a series of devices and a method for direct access not dealing with branch vessels allowing for navigation without wire. The column strength of guide catheter can break through heavily calcified lesion and operate in combination with low profile balloon catheter can pave way proximal through the SFA.
- In one embodiment, it is an object of the instant system to introduce a series of devices and a method for advancing distal to proximal in order to reduce the onset of shower of emboli below the knee into the territory of the foot. Positioning an embolic protection device at or near the puncture site will permit safe removal of dislodged plaque or emboli generated during the access and angioplasty procedure.
- In one embodiment, it is an object of the instant system to introduce a series of shorter devices and an accompanying method which permit significantly greater user control while treating claudication or critical limb ischemia within the lower extremities, peripheral arterial disease and specifically on the superficial femoral and proximal popliteal artery (SFPA), lower SFA
- In one embodiment, it is an object of the instant system to utilize a wide variety of established and evolving endovascular techniques to treat PAD including percutaneous transluminal angioplasty (PTA) with balloon dilation, stents, endografts, atherectomy, laser, cutting balloons, drug-coated balloon angioplasty, cryoplasty, percutaneous thrombectomy and brachytherapy exist.
- As an alternative, the guide catheter can be advanced in stages with the balloon or the guidewire can be advanced independently to access the most proximal location in the vessel prior to introduction of the balloon catheter and paving can advance proximal to distal (i.e in the direction of the puncture site).
- The foregoing has outlined the more pertinent and important features of the present invention in order that the detailed description of the invention that follows may be better understood, and the present contributions to the art may be more fully appreciated. It is of course not possible to describe every conceivable combination of components and/or methodologies, but one of ordinary skill in the art may recognize that many further combinations or permutations are possible. Accordingly, the novel architecture described below is intended to embrace all such alterations, modifications, and variations that fall within the spirit and scope of the appended claims.
- There has thus been outlined, rather broadly, the more important features of the retrograde approach to treatment in the area of the SFA, including all applicable methods, systems or series of accompanying systems, apparatuses and embodiments in order that the detailed description thereof that follows may be better understood, and in order that the present contribution to the art may be better appreciated. There are additional features of the invention that will be described hereinafter and which will form the subject matter of the claims appended hereto.
- In this respect, before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and to the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced and carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting.
- These together with other objects of the invention, along with the various features of novelty, which characterize the invention, are pointed out with particularity in the claims annexed to and forming a part of this disclosure. For a better understanding of the invention, its operating advantages and the specific objects attained by its uses, reference should be made to the accompanying drawings and descriptive matter in which there are illustrated preferred embodiments of the invention.
- To the accomplishment of the foregoing and related ends, certain illustrative aspects are described herein in connection with the following description and the annexed drawings. These aspects are indicative of the various ways in which the principles disclosed herein can be practice and all aspects and equivalents thereof are intended to be within the scope of the claimed subject matter. Other advantages and novel features will become apparent from the following detailed description when considered in conjunction with the drawings.
- Advantages of the present system will be apparent from the following detailed description of exemplary embodiments thereof, which description should be considered in conjunction with the accompanying drawings, in which having thus described the system in general terms, reference will now be made to the accompanying drawings, which are not necessarily drawn to scale, and wherein:
-
FIG. 1 illustrates cross sectional view of a human limb further illustrating the anatomy of the limb with the arteries highlighted and further illustrating an access point for a retrograde approach to treating blockages of the lower portion of the superficial femoral artery or lower SFA. -
FIG. 2 illustrates a cross sectional view of the procedural tract illustrating the access point for retrograde approach to treating blockages of the lower SFA. Further illustrated is the puncture site for sheath access through Popliteal behind the knee. Herein, the system being utilized introduces a 3F introducer sheath, a guide catheter for advancing toward an area of dense plaque within the lower SFA and a balloon in a deflated orientation. The blood flow direction is illustrated and thus retrograde access is being performed herein. -
FIG. 3 illustrates cross sectional view of the access point for retrograde approach to treating blockages of the lower SFA. Further illustrated is the puncture site for sheath access through Popliteal behind the knee. Herein, the system being utilized introduces a 3F introducer sheath, a guide catheter for advancing toward an area of dense plaque within the lower SFA and a balloon in an inflated orientation in order to free up the blockage in a retrograde paving technique which opens up the calcified lesion. -
FIG. 4 . illustrates a right side view, detailed cutaway of the anatomy of limb showing access point for retrograde approach to treating lower SFA, illustrating the full path for entry and delivery from the popliteal entry to superficial femoral artery. -
FIG. 5 . illustrates a left side view, detailed cutaway of the anatomy of the limb showing access point for retrograde approach to treating lower SFA, illustrating the entirety of the entry and delivery path from the popliteal entry to superficial femoral artery in the color green. In this figure, the pathway is illuminated from the puncture site through popliteal behind the knee to the blockage are in the lower SFA. - The detailed description set forth below in connection with the appended drawings is intended as a description of presently preferred embodiments of the system and does not represent the only forms in which the present system may be constructed and/or utilized. The description sets forth the functions and the sequence of steps for constructing and operating the system in connection with the illustrated embodiments.
-
FIG. 1 illustrates a cross sectional view of a human limb further illustrating the anatomy of the limb with the arteries highlighted and further illustrating anaccess point 10 for a retrograde approach to treating blockages of the lower superficial femoral artery (SFA). -
FIG. 2 illustrates a cross sectional view of theprocedural tract 5 illustrating theaccess point 10 for retrograde approach to treating blockages of the lower SFA, further illustrating the instrumentation utilized at theaccess point 10 or the puncture site and for sheath access through the Popliteal andpopliteal artery 15 behind the knee. Herein, the system being utilized introduces anintroducer sheath 20, aguide catheter 30 for advancing toward an area ofdense plaque 40 within thelower SFA 50 and aballoon 60 in a deflated orientation. - In one embodiment, the
introducer sheath 20 utilized may be a three French or3F introducer sheath 20. The bloodflow direction indicator 70 is illustrated, thus denoting that retrograde access is being performed herein. Again, aguide wire 80 may also be utilized in conjunction with the currently described system. -
FIG. 3 illustrates a further cross-sectional view of theprocedural tract 5 illustrating theaccess point 10 and the system deployed further illustrating theaccess point 10 through the Popliteal andpopliteal artery 15 behind the knee for retrograde approach to treating blockages of thelower SFA 50. Further illustrated is the puncture site for sheath access through Popliteal behind the knee. Herein, the system being utilized introduces a3F introducer sheath 20, aguide catheter 30 for advancing toward an area ofdense plaque 40 within thelower SFA 50 and theballoon 60, now in the inflated orientation in order to free up the blockage in a retrograde paving technique which opens up the calcified lesion. - Once again, the blood
flow direction indicator 70 is illustrated, thus denoting that retrograde access is being performed herein. Additionally illustrated herein is aguidewire 80, which may also be utilized. - Further, as the direction of the blood flow is opposed to direction of operation of the system and thus the initial the paving as illustrated constitutes retrograde access being performed. In an alternative methodology, the guide catheter may be advanced in stages with the balloon.
- In an additional embodiment, the guidewire may be advanced independently to access the most proximal location in the vessel prior to introduction of the balloon catheter and paving can advance proximal to distal (i.e in the direction of the puncture site).
-
FIG. 4 . illustrates a right-side view of a more detailed cutaway of the anatomy of thelimb 100 illustrating the entirety of the entry anddelivery tract 5 from thepopliteal artery 15 entry to superficial femoral artery in the color green. In this figure, the pathway is illuminated from the puncture site through popliteal behind the knee to the blockage are in the lower SFA. -
FIG. 5 . illustrates a left side view, detailed cutaway of the anatomy of thelimb 105 showing access point for retrograde approach to treating lower SFA, illustrating the entirety of the entry anddelivery path 5 from thepopliteal artery 15 entry to superficial femoral artery in the color green. In this figure, the pathway is illuminated from the puncture site through popliteal behind the knee to the blockage are in the lower SFA. - In one embodiment, a method of treating a blockage of the superior femoral artery (“SFA”) is disclosed, which involves the steps of:
- selecting an area behind a knee of the affected limb;
- creating a puncture site behind the knee;
- entering the puncture site through the popliteal;
- advancing retrograde through the popliteal toward a lower SFA region;
- utilizing an introducer sheath having a proximal end, a distal end, an opening at the distal end, and a passage in communication with the opening at the distal end, the one or more prostheses being movably disposed in the passage;
- utilizing a guide catheter;
- utilizing an expandable member;
- positioning the distal end of the introducer sheath and the expandable member at the treatment site; and
- proximally retracting the introducer sheath relative to the expandable member and thereby cause the one or more prostheses to pass through the opening of the introducer sheath for expansion at the treatment site via the expandable member.
- Additionally, the method includes the use of a guide wire and where it is advanced in stages. In another embodiment, the introducer sheath comprises a three (3) French introducer sheath.
- In yet another embodiment, the method includes additional steps of advancing the guidewire independently to access the most proximal location in a vessel and introducing a balloon. In another embodiment, the method involves the steps of advancing the guide catheter and paving proximal to distal in the direction of the puncture site and advancing distal to proximal in order to reduce a shower of emboli below the knee into the territory of the foot.
- In an alternate embodiment, the method of treating a blockage of the superior femoral artery comprises the step of positioning an embolic protection device in the region proximal to the puncture site to permit safe removal of dislodged plaque or emboli generated during the access and angioplasty procedure and comprises the step of removing dislodged plaque or emboli generated during the access and angioplasty procedure.
- Another aspect of the method of treating a blockage of the superior femoral artery of claim 1 includes the step of advancing directly from the popliteal to the SFA and access not dealing with branch vessels allowing for navigation without wire and optionally utilizing a system which does not include the guide wire for navigation of the popliteal and SFA.
- Furthermore, the method of treating a blockage of the superior femoral artery of further comprises the step of selecting or calibrating a measure of column strength of the guide catheter can break through heavily calcified lesion and the step of operating in combination with a low-profile balloon catheter to advance proximally through the SFA.
- In yet another embodiment, the method of treating a blockage of the superior femoral artery of further comprises the step of advancing the guide catheter in a method selected from the group consisting of in stages with a balloon and independently, and may also include the steps of:
- advancing the guide catheter independently;
- accessing the most proximal location in the vessel prior to introduction of the balloon catheter; and
- paving proximally to distally in the direction of the puncture site to reduce shower of emboli below the knee into the territory of the foot.
- Finally, in yet another embodiment, the method of treating a blockage of the superior femoral artery comprises the step of positioning an embolic protection device at or near the puncture site will permit safe removal of dislodged plaque or emboli generated during an access and angioplasty procedure and the step of utilizing a retrograde paving technique to open the calcified lesion.
- In yet another embodiment, a system for treating a blockage of the superior femoral artery is disclosed, which includes:
- a puncture mechanism;
- selecting an area behind a knee of the affected limb;
- creating a puncture site behind the knee;
- entering the puncture site through the popliteal;
- advancing retrograde through the popliteal toward a lower SFA region;
- an introducer sheath;
- a guide catheter; and
- a balloon.
- Additionally, the system for treating a blockage of the superior femoral artery may utilize a low profile balloon catheter to pave proximal through the SFA, while maximizing the column strength of the guide catheter to break through heavily calcified lesion.
- In yet another embodiment, a method of delivering one or more prostheses to a treatment site is disclosed, involving the steps of providing a catheter, and using a sheath having a proximal end, a distal end, an opening at the distal end, and a passage in communication with the opening, the one or more prostheses being movably disposed in the passage with an expandable member near the distal end of the sheath, the one or more prostheses being positionable over the expandable member, and a valve member near the distal end of the sheath adapted for selectively retaining a first set of prostheses within the passage and to engage the one or more prostheses whereby the one or more prostheses may be moved relative to the expandable member by moving the sheath; positioning the distal end of the sheath and the expandable member at the treatment site; and proximally retracting the sheath relative to the expandable member to move the valve member and thereby cause a first set of prostheses to pass through the opening of the sheath for expansion at the treatment site via the expandable member while retaining a second set of prostheses within the passage.
Claims (18)
1. A method of treating a blockage of the superior femoral artery (“SFA”) comprising the steps of:
selecting an area behind a knee of the affected limb;
creating a puncture site behind the knee;
entering the puncture site through the popliteal;
advancing retrograde through the popliteal toward a lower SFA region;
utilizing an introducer sheath having a proximal end, a distal end, an opening at the distal end, and a passage in communication with the opening at the distal end, the one or more prostheses being movably disposed in the passage;
utilizing a guide catheter;
utilizing an expandable member
positioning the distal end of the introducer sheath and the expandable member at the treatment site; and
proximally retracting the introducer sheath relative to the expandable member and thereby cause the one or more prostheses to pass through the opening of the introducer sheath for expansion at the treatment site via the expandable member.
2. The method of treating a blockage of the superior femoral artery of claim 1 further comprising utilizing a guide wire.
3. The method of treating a blockage of the superior femoral artery of claim 1 wherein the introducer sheath comprises a three (3) French introducer sheath.
4. The method of treating a blockage of the superior femoral artery of claim 1 wherein the guide catheter is advanced in stages.
5. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of advancing the guidewire independently to access the most proximal location in a vessel.
6. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of introducing a balloon.
7. The method of treating a blockage of the superior femoral artery of claim 4 further comprising the step of advancing the guide catheter and paving proximal to distal in the direction of the puncture site.
8. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of advancing distal to proximal in order to reduce a shower of emboli below the knee into the territory of the foot.
9. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of positioning an embolic protection device in the region proximal to the puncture site to permit safe removal of dislodged plaque or emboli generated during the access and angioplasty procedure.
10. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of removing dislodged plaque or emboli generated during the access and angioplasty procedure.
11. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of advancing directly from the popliteal to the SFA and access not dealing with branch vessels allowing for navigation without wire.
12. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of utilizing a system which does not include the guide wire for navigation of the popliteal and SFA.
13. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of selecting or calibrating a measure of column strength of the guide catheter can break through heavily calcified lesion.
14. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of operating in combination with a low-profile balloon catheter to advance proximally through the SFA.
15. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of advancing the guide catheter in a method selected from the group consisting of in stages with a balloon and independently.
16. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the steps of:
advancing the guide catheter independently;
accessing the most proximal location in the vessel prior to introduction of the balloon catheter; and
paving proximally to distally in the direction of the puncture site to reduce shower of emboli below the knee into the territory of the foot.
17. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of positioning an embolic protection device at or near the puncture site will permit safe removal of dislodged plaque or emboli generated during an access and angioplasty procedure.
18. The method of treating a blockage of the superior femoral artery of claim 1 further comprising the step of utilizing a retrograde paving technique to open the calcified lesion.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/702,767 US20200171282A1 (en) | 2018-12-04 | 2019-12-04 | System and method for treatment of the claudification of the superficial femoral and proximal popliteal artery |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862775055P | 2018-12-04 | 2018-12-04 | |
US16/702,767 US20200171282A1 (en) | 2018-12-04 | 2019-12-04 | System and method for treatment of the claudification of the superficial femoral and proximal popliteal artery |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200171282A1 true US20200171282A1 (en) | 2020-06-04 |
Family
ID=70849005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/702,767 Pending US20200171282A1 (en) | 2018-12-04 | 2019-12-04 | System and method for treatment of the claudification of the superficial femoral and proximal popliteal artery |
Country Status (1)
Country | Link |
---|---|
US (1) | US20200171282A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11116943B2 (en) | 2018-10-09 | 2021-09-14 | Limflow Gmbh | Methods for accessing pedal veins |
US11241304B2 (en) | 2006-04-20 | 2022-02-08 | Limflow Gmbh | Method for fluid flow through body passages |
US11446170B2 (en) | 2004-09-08 | 2022-09-20 | Limflow Gmbh | Minimally invasive surgical apparatus and methods |
US11471262B2 (en) | 2013-03-08 | 2022-10-18 | Limflow Gmbh | Methods for targeting a body passage to effect fluid flow |
US11612397B2 (en) | 2019-11-01 | 2023-03-28 | Limflow Gmbh | Devices and methods for increasing blood perfusion to a distal extremity |
US11826504B2 (en) | 2017-04-10 | 2023-11-28 | Limflow Gmbh | Methods for routing a guidewire from a first vessel and through a second vessel in lower extremity vasculature |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090076593A1 (en) * | 2007-09-14 | 2009-03-19 | Cook Incorporated | Expandable device for treatment of a stricture in a body vessel |
US20100036475A1 (en) * | 2006-04-27 | 2010-02-11 | Wilifrido Castaneda | Methods and apparatus for extraluminal femoropopliteal bypass graft |
US20140142677A1 (en) * | 2012-04-23 | 2014-05-22 | Pq Bypass, Inc. | Methods and systems for bypassing occlusions in a femoral artery |
US20150174363A1 (en) * | 2013-12-20 | 2015-06-25 | Boston Scientific Scimed, Inc. | Integrated catheter system |
US20180360461A1 (en) * | 2017-06-14 | 2018-12-20 | William Joseph Drasler | Positionable Perivalvular Occlusion Device |
-
2019
- 2019-12-04 US US16/702,767 patent/US20200171282A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100036475A1 (en) * | 2006-04-27 | 2010-02-11 | Wilifrido Castaneda | Methods and apparatus for extraluminal femoropopliteal bypass graft |
US20090076593A1 (en) * | 2007-09-14 | 2009-03-19 | Cook Incorporated | Expandable device for treatment of a stricture in a body vessel |
US20140142677A1 (en) * | 2012-04-23 | 2014-05-22 | Pq Bypass, Inc. | Methods and systems for bypassing occlusions in a femoral artery |
US20150174363A1 (en) * | 2013-12-20 | 2015-06-25 | Boston Scientific Scimed, Inc. | Integrated catheter system |
US20180360461A1 (en) * | 2017-06-14 | 2018-12-20 | William Joseph Drasler | Positionable Perivalvular Occlusion Device |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11446170B2 (en) | 2004-09-08 | 2022-09-20 | Limflow Gmbh | Minimally invasive surgical apparatus and methods |
US11241304B2 (en) | 2006-04-20 | 2022-02-08 | Limflow Gmbh | Method for fluid flow through body passages |
US11471262B2 (en) | 2013-03-08 | 2022-10-18 | Limflow Gmbh | Methods for targeting a body passage to effect fluid flow |
US11826504B2 (en) | 2017-04-10 | 2023-11-28 | Limflow Gmbh | Methods for routing a guidewire from a first vessel and through a second vessel in lower extremity vasculature |
US11116943B2 (en) | 2018-10-09 | 2021-09-14 | Limflow Gmbh | Methods for accessing pedal veins |
US11129965B2 (en) | 2018-10-09 | 2021-09-28 | Limflow Gmbh | Devices and methods for catheter alignment |
US11311700B2 (en) | 2018-10-09 | 2022-04-26 | Limflow Gmbh | Methods for accessing pedal veins |
US11478614B2 (en) | 2018-10-09 | 2022-10-25 | Limflow Gmbh | Method for accessing pedal veins for deep vein arterialization |
US11850379B2 (en) | 2018-10-09 | 2023-12-26 | Limflow Gmbh | Devices and methods for catheter alignment |
US11612397B2 (en) | 2019-11-01 | 2023-03-28 | Limflow Gmbh | Devices and methods for increasing blood perfusion to a distal extremity |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200171282A1 (en) | System and method for treatment of the claudification of the superficial femoral and proximal popliteal artery | |
US6533800B1 (en) | Devices and methods for preventing distal embolization using flow reversal in arteries having collateral blood flow | |
Dattilo et al. | Critical limb ischemia: endovascular strategies for limb salvage | |
Veith et al. | Improved strategies for secondary operations on infrainguinal arteries | |
Nakada | Acucise endopyelotomy | |
Kessel et al. | Endovascular stent-grafts for superficial femoral artery disease: results of 1-year follow-up | |
Marks et al. | Duplex guided balloon angioplasty of failing infrainguinal bypass grafts | |
He et al. | Two new methods of supine venographically guided popliteal vein puncture: a retrospective study | |
Ferretto et al. | ViPS (Viabahn Padova Sutureless) technique: preliminary results in the treatment of peripheral arterial disease | |
US20210378851A1 (en) | System and Method for Treating Critical Limb Ischemia (CLI) via the Superficial Femoral Arteries (SFA) | |
Minar et al. | New stents for SFA | |
Abahji et al. | Stenting of the superficial femoral artery after suboptimal balloon angioplasty: one-year results | |
RU221338U1 (en) | Guiding catheter-introducer for retrograde distal access to the arteries of the lower extremities | |
RU2799059C1 (en) | Method of endovascular revascularization of chronic occlusions of peripheral stents in the femoropopliteal segment | |
RU2780929C1 (en) | Method for forming an arteriovenous fistula for the prevention of patency disorders of the main arteries of the lower extremities | |
Venher et al. | Endovascular angioplasty for multi-level stenotic-occlusive lesions of the femoral-distal arterial bed in cases of stenotic-occlusive process of the tibial arteries | |
Cardon et al. | Value of cutting balloon angioplasty for limb salvage in patients with obstruction of popliteal and distal arteries | |
Ou et al. | Other Access | |
Tittley et al. | Radiological intervention for the failing in situ vein bypass | |
Khaliq et al. | Lower‐Extremity Venous Stenting | |
Gaylis, H., Mieny, CJ & Stein | Some observations on reconstructive arterial surgery in atherosclerosis obliterans of the lower extremities | |
Rigatelli et al. | Iliac Artery Stenosis | |
Labeb et al. | Hybrid Revascularization by Common Femoral Artery Endarterectomy and Proximal or Distal Angioplasty in Patients with Critical Lower Limb Threatening Ischemia | |
Inoue et al. | A Case of Carotid Artery Stenting through Surgical Exposure and Direct Puncture of the Femoral Artery with Severe Arteriosclerosis Obliterans: A Technical Note | |
Jayaraj et al. | Iliac vein stenting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |